In summary, weekly Nab-PTX monotherapy schedule of 130 mg/m2 on days 1 and 8 of a 21-day cycle was efficacious and well-tolerated for patients with pretreated advanced NSCLC in Chinese population, regardless of line of therapy, prior taxane exposure or SPARC expression. Here, SPARC is linked to non-small cell lung carcinoma.